<SEC-DOCUMENT>0001654954-26-003979.txt : 20260428
<SEC-HEADER>0001654954-26-003979.hdr.sgml : 20260428
<ACCEPTANCE-DATETIME>20260428073155
ACCESSION NUMBER:		0001654954-26-003979
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260428
FILED AS OF DATE:		20260428
DATE AS OF CHANGE:		20260428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		26903150

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		PROVINCE COUNTRY:   	X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		PROVINCE COUNTRY:   	X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a1866c.htm
<DESCRIPTION>BREZTRI APPROVED IN THE US FOR ASTHMA
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Services - www.issuerservices.net -->
<!-- Copyright 2026 Issuer Services -->
<title>a1866c</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 6-K</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Report
of Foreign Issuer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Rule 13a-16 or 15d-16 of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of April 2026&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: 001-11960</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1
Francis Crick Avenue</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
Biomedical Campus</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
CB2 0AA</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">United
Kingdom</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F X Form 40-F __</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes __
No X</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If
&#x201C;Yes&#x201D; is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">INDEX
TO EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Breztri
approved in the US for asthma</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
28 April 2026</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000; font-size: 13px">
Breztri</font><font style="color: #000000">&#xA0;</font><font style="font-weight: bold; color: #000000; font-size: 13px">approved
in the US for asthma as first and only triple therapy for patients
12 years of age and older</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Approval based on KALOS and LOGOS Phase III trials demonstrating
statistically significant and clinically meaningful benefits of
AstraZeneca's single-inhaler fixed-dose triple therapy compared
with inhaled dual therapy</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Approval is second indication for Breztri beyond COPD
&#xA0;&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
AstraZeneca's fixed-dose triple-combination
therapy&#xA0;</font><font style="font-style: italic; color: #000000">Breztri
Aerosphere</font><font style="color: #000000">&#xA0;(budesonide/glycopyrrolate/formoterol
fumarate or BGF 320/36/9.6lg) has been approved in the US for the
maintenance treatment of asthma in adult and paediatric patients 12
years of age and older.&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;is a single-inhaler that combines the
efficacy of&#xA0;corticosteroid/long-acting beta2-agonist
(ICS/LABA) medicines&#xA0;with a long-acting muscarinic antagonist
(LAMA).&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;(320/18/9.6lg)&#xA0;was approved in the US
in 2020 to treat adults with chronic obstructive pulmonary disease
(COPD) and was prescribed to more than 6.8 million patients
globally in 2025.</font><font style="font-size: 70%; vertical-align: top; color: #000000">1,2</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The approval by the US Food and Drug Administration (FDA)&#xA0;was
based on efficacy and safety data from the Phase III&#xA0;KALOS and
LOGOS trials investigating&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;in a broad population consisting of patients
with asthma, with or without a recent asthma
exacerbation.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font><font style="color: #000000">&#xA0;In
these trials,&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;demonstrated a statistically significant and
clinically meaningful improvement in lung function compared with
dual-combination inhaled ICS/LABA.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font><font style="color: #000000">&#xA0;In
a key secondary endpoint,&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;also demonstrated a rapid onset of action
with a significant improvement from baseline in lung function
within five minutes after the first dose.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;is
a maintenance therapy and is not used to relieve sudden breathing
problems and will not replace a rescue inhaler.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Njira Lugogo, MD, Clinical Professor, Division of Pulmonary and
Critical Care Medicine, Department of Internal Medicine, University
of Michigan, said:&#xA0;"Despite the availability of dual
maintenance therapy, many patients are still at risk for
exacerbations and experience daily breathing difficulties, reduced
lung function and the ongoing fear of worsening symptoms. The FDA
approval of&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;as the only maintenance triple therapy for
people with asthma 12 years of age and older marks a pivotal moment
in helping those living with this debilitating disease breathe
better, sooner."</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #830051; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Ruud Dobber, Executive Vice
President,&#xA0;BioPharmaceuticals&#xA0;Business Unit, AstraZeneca,
said: "As the fastest growing fixed-dose triple-combination therapy
in COPD,&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;is already improving outcomes for people
suffering with COPD, and we are proud to extend its benefits to
asthma patients. The FDA's approval of&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;in asthma demonstrates how our innovative
science continues to bring new solutions for patients with
respiratory diseases."</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
There are 27 million people living with asthma in the
US,</font><font style="font-size: 70%; vertical-align: top; color: #000000">4</font><font style="color: #000000">&#xA0;around
half of whom continue to be uncontrolled on dual therapies, leading
to inflammation and muscle tightening in the airway
(bronchoconstriction) that cause wheezing, breathlessness, chest
tightness, coughing&#xA0;exacerbations and even
death.</font><font style="font-size: 70%; vertical-align: top; color: #000000">5-7</font><font style="color: #000000">&#xA0;Nearly
10 million asthma attacks still occur each year in the
US.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Results from&#xA0;</font><font style="text-decoration: underline; color: #0000FF">KALOS and
LOGOS</font><font style="color: #000000">&#xA0;were published
in&#xA0;</font><font style="font-style: italic; text-decoration: underline; color: #0000FF">The
Lancet Respiratory Medicine</font><font style="color: #000000">&#xA0;in February 2026.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font><font style="color: #000000">&#xA0;There
were no new safety or tolerability signals identified
for&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;in the trials.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">
Breztri</font><font style="color: #000000">&#xA0;is a
single-inhaler fixed-dose triple-combination therapy approved for
the treatment of COPD in adults&#xA0;in 90 countries worldwide
including the US, EU, China and Japan. Regulatory filings
for&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;in asthma are currently under review in
other major regions including the EU, Japan and
China.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Notes</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #FF0000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Asthma</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Asthma is a prevalent, chronic respiratory disease affecting as
many as 262 million people worldwide,</font><font style="font-size: 70%; vertical-align: top; color: #000000">8</font><font style="color: #000000">&#xA0;including
27 million in the US.</font><font style="font-size: 70%; vertical-align: top; color: #000000">4</font><font style="color: #000000">&#xA0;When
uncontrolled, inflammation and muscle tightening in the airway
(bronchoconstriction) may cause wheezing, breathlessness, chest
tightness, coughing, and even death.</font><font style="font-size: 70%; vertical-align: top; color: #000000">5-7</font><font style="color: #000000">&#xA0;Many
patients remain uncontrolled despite the availability of standard
of care medicines and continue to experience significant
limitations on lung function and reduced quality of
life.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6,7</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
KALOS and LOGOS Phase III trials</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
KALOS and LOGOS were replicate confirmatory, randomised,
double-blind, double-dummy, parallel group, multi-centre,
24-to-52-week variable length Phase III trials to assess the
efficacy and safety of&#xA0;</font><font style="font-style: italic; color: #000000">Breztri</font><font style="color: #000000">&#xA0;</font><font style="font-style: italic; color: #000000">Aerosphere</font><font style="color: #000000">&#xA0;compared with&#xA0;S</font><font style="font-style: italic; color: #000000">ymbicort</font><font style="color: #000000">&#xA0;(budesonide/formoterol fumarate, a marketed
therapeutic option), PT009&#xA0;(budesonide/formoterol fumarate in
an&#xA0;</font><font style="font-style: italic; color: #000000">Aerosphere</font><font style="color: #000000">&#xA0;formulation) and
the&#xA0;</font><font style="font-style: italic; color: #000000">Symbicort</font><font style="color: #000000">&#xA0;and
PT009 treatment groups combined.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,9,10</font><font style="color: #000000">&#xA0;KALOS
and LOGOS included approximately 4,300 randomised
patients.&#xA0;&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The primary endpoints for the two individual trials were a change
from baseline in forced expiratory volume in 1 second
(FEV</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">1</font><font style="color: #000000">)
area under the curve 0 to 3 hours (AUC</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">0-3</font><font style="color: #000000">)
at Week 24 and trough FEV</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">1</font><font style="color: #000000">&#xA0;over
12-24 weeks and over 24 weeks.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3,9,10</font><font style="color: #000000">&#xA0;The
primary endpoints and treatment comparisons in the KALOS and LOGOS
trials differed according to regulatory submission approaches. In
the data package submitted to the US FDA, the primary lung
function&#xA0;endpoint was change from baseline in
FEV</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">1</font><font style="color: #000000">&#xA0;AUC</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">0-3</font><font style="color: #000000">&#xA0;at
week 24, and the key secondary endpoint was change from baseline in
morning pre-dose trough FEV</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">1</font><font style="color: #000000">&#xA0;at
week 24, compared to PT009.</font><font style="font-size: 70%; vertical-align: top; color: #000000">3</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
Breztri/Trixeo Aerosphere</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Budesonide/glycopyrronium/formoterol fumarate or
budesonide/glycopyrrolate/formoterol fumarate, is approved under
the brand name&#xA0;</font><font style="font-style: italic; color: #000000">Breztri
Aerosphere</font><font style="color: #000000">&#xA0;in Japan, China
and the US, and&#xA0;</font><font style="font-style: italic; color: #000000">Trixeo
Aerosphere</font><font style="color: #000000">&#xA0;in the EU, is a
single-inhaler, fixed-dose triple-combination of formoterol
fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic
antagonist (LAMA), with budesonide, an ICS, and delivered via
the&#xA0;</font><font style="font-style: italic; color: #000000">Aerosphere</font><font style="color: #000000">&#xA0;pMDI.&#xA0;</font><font style="font-style: italic; color: #000000">Breztri/Trixeo
Aerosphere</font><font style="color: #000000">&#xA0;is approved to
treat adults with COPD in 90 countries worldwide including the US,
EU, China, Japan, and was&#xA0;prescribed to more than 6.8 million
patients globally in 2025.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca in Respiratory &amp; Immunology</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Respiratory &amp; Immunology, part of AstraZeneca
BioPharmaceuticals, is a key disease area and growth driver to the
Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca is an established leader in respiratory care with a
50-year heritage and a growing portfolio of medicines in
immune-mediated diseases. The Company is committed to addressing
the vast unmet needs of these chronic, often debilitating, diseases
with a pipeline and portfolio of inhaled medicines, biologics and
new modalities aimed at previously unreachable biologic targets.
Our ambition is to deliver life-changing medicines that help
eliminate COPD as a leading cause of death, eliminate asthma
attacks and achieve clinical remission in immune-mediated
diseases.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp;
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit&#xA0;</font><font style="text-decoration: underline; color: #0000FF">astrazeneca.com</font><font style="color: #000000">&#xA0;and
follow the Company on Social Media&#xA0;</font><font style="text-decoration: underline; color: #0000FF">@AstraZeneca</font><font style="color: #000000">.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Contacts</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
For details on how to contact the Investor Relations Team, please
click&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.
For Media contacts, click&#xA0;</font><font style="text-decoration: underline; color: #0000FF">here</font><font style="color: #000000">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
References</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">1.&#xA0;&#xA0; AstraZeneca. Breztri Aerosphere
approved in the US for the maintenance treatment of COPD. Press
Release. 24 July 2020. Available at:</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html</font><font style="color: #000000">.
[Last accessed: April 2026].</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;
AstraZeneca. Data On File. REF-325003.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">3.&#xA0;&#xA0; Papi A, Wise R, Jackson D et al.
Budesonide-glycopyrronium-formoterol fumarate dihydrate in
uncontrolled asthma (KALOS and LOGOS): twin multicentre,
double-blind, double-dummy, parallel-group, randomised, phase 3
trials</font><font style="font-style: italic; color: #000000">. The
Lancet Respiratory Medicine</font><font style="color: #000000">.
2026;14:350-362.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">4.&#xA0;&#xA0; U.S. Centers for Disease Control
and Prevention (CDC). Most Recent Asthma Data.
[Online].</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">Available at:</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">[Last
accessed: April 2026].</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">5.&#xA0;&#xA0; Fernandes AG, et al. Risk factors
for death in patients with severe asthma.&#xA0;</font><font style="font-style: italic; color: #000000">J Bras
Pneumol</font><font style="color: #000000">.
2014;40(4):364-372.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">6.&#xA0;&#xA0; Davis J, et al. Burden of asthma
among patients adherent to ICS/LABA: A real-world
study.&#xA0;</font><font style="font-style: italic; color: #000000">J Asthma</font><font style="color: #000000">. 2019 Mar;56(3):332-340.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">7.&#xA0;&#xA0; Buhl R, et al. One-year follow up
of asthmatic patients newly initiated on treatment with medium- or
high-dose inhaled corticosteroid-long-acting b2-agonist in UK
primary care settings.&#xA0;</font><font style="font-style: italic; color: #000000">Respir Med</font><font style="color: #000000">. 2020 Feb;162:105859.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">8.&#xA0;&#xA0; Global Asthma Network. The Global
Asthma Report 2022. [Online]. Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF">http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf</font><font style="color: #000000">.
[Last accessed: April 2026].</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">9.&#xA0;&#xA0;&#xA0;Clinicaltrials.gov. Study to
Assess PT010 in Adult and Adolescent Participants with Inadequately
Controlled Asthma (KALOS) [Online]. Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF">https://clinicaltrials.gov/study/NCT04609878?limit=25&amp;term=KALOS&amp;rank=1</font><font style="color: #000000">.
[Last accessed: April 2026].</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">10.&#xA0; Clinicaltrials.gov. Study to Assess
PT010 in Adult and Adolescent Participants with Inadequately
Controlled Asthma (LOGOS) [Online]. Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF">https://clinicaltrials.gov/study/NCT04609904?limit=25&amp;term=LOGOS&amp;rank=4</font><font style="color: #000000">.&#xA0;[Last
accessed: April 2026].</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Matthew Bowden</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Company Secretary</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
PLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
Date:</font> <font style="font-weight: bold">28 April
2026</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By: /s/
Matthew Bowden</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Matthew Bowden</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Company Secretary</font></div>
</td>
</tr></table>
</div>
<br>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
